CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

Journal of Ocular Biology, Diseases, and Informatics

Volumn 3, Issue 2, 2010, Pages 53-59

  Imai, Daisuke ^a   Mori, Keisuke ^a   Horie Inoue, Kuniko ^a   Gehlbach, Peter L ^b   Awata, Takuya ^a   Inoue, Satoshi ^a   Yoneya, Shin ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Complement factor H; Genetic biomarker; High temperature requirement A 1; Pigment epitheliumderived factor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; HIGH TEMPERATURE REQUIREMENT A1; PIGMENT EPITHELIUM DERIVED FACTOR; SERINE PROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EXUDATIVE MACULAR DEGENERATION; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79955796065     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-010-9055-1     Document Type: Article

References (45)

1. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology. 2000;107:2224-32.
2. Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results. AREDS report no. 11. Arch Ophthalmol. 2003;121:1621-4.
3. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study. AREDS report no. 19. Am J Ophthalmol. 2005;112:533-9.
4. Klein R, Peto T, Bird AC, Vannewkirk MR. The epidemiology of agerelatedmacular degeneration. Am J Ophthalmol. 2004;137:486-95.
5. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-9. (Pubitemid 40530070)
6. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of agerelated macular degeneration. Science. 2005;308:419-21. (Pubitemid 40530081)
7. Edward AO, Ritter 3rd R, Abel KJ, Manning A, Panhuysen C, Farrer LA, et al. Complement factor H polymorphism and agerelated macular degeneration. Science. 2005;314:989-92.
8. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hageman JL, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227-32. (Pubitemid 40696361)
9. Li M, Atmaca-Sonmez P, Othman M, Branham KE, Khanna R, Wade MS, et al. CFH haplotypes without the Y402H cording variant show strong association with susceptibility to age-related macular degeneration. Nat Genet. 2006;38:1049-54. (Pubitemid 44325931)
10. Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006;38:1055-9. (Pubitemid 44325932)
11. Jackobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77:389-407. (Pubitemid 41192646)
12. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-36. (Pubitemid 41631297)
13. Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet. 2006;78:852-64.
14. Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008;40:892-6. (Pubitemid 351913654)
15. Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA. 2007;104:16227-32. (Pubitemid 350099389)
16. DeWan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989-92. (Pubitemid 44749943)
17. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006;314:992-3. (Pubitemid 44749944)
18. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-62. (Pubitemid 27427368)
19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-9. (Pubitemid 20066716)
20. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu HJ, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-8. (Pubitemid 29329995)
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med. 1995;1:27-31.
22. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol. 2001;89:323-33. (Pubitemid 33063300)
23. Holkamp NM, Bouk N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol. 2002;134:220-7. (Pubitemid 34831826)
24. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002;134:348-53.
25. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-16.
26. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. (Pubitemid 44511557)
27. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-5. (Pubitemid 41073112)
28. Brantley Jr MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168-73. (Pubitemid 350181136)
29. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93:610-3.
30. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635-9. (Pubitemid 34826636)
31. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun. 2005;333:679-85. (Pubitemid 40854214)
32. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383-94. (Pubitemid 36935331)
33. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR and LRP6. Invest Ophthalmol Vis Sci. 2006;47:329-35. (Pubitemid 46780832)
34. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular agerelated macular degeneration. Hum Mol Genet. 2006;15:2955-61. (Pubitemid 44446814)
35. Mori K, Horie-Inoue K, Gehlbach PL, Takita H, Kabasawa S, Kawasaki I, et al. Phenotype and genotype characteristics of agerelated macular degeneration in a Japanese population. Ophthalmology. 2010;117:928-38.
36. Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, Takita H, et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology. 2010;117: in press.
37. Boekhorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration. Ophthalmology. 2008;115:1899-903.
38. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672-8.
39. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res. 2009;15:5297-302.
40. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82:99-110. (Pubitemid 43063401)
41. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol. 2002;134:220-7. (Pubitemid 34831826)
42. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188:253-63. (Pubitemid 32622916)
43. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2002;43:2428-34. (Pubitemid 34700678)
44. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15-22.
45. Chan WM, Lai TY, Tano Y, Liu DTL, Li KKW, Lam DS. Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol. 2006;50:161-9.